Jarvis Michael F, Bianchi Bruce, Uchic John T, Cartmell Jayne, Lee Chih-Hung, Williams Michael, Faltynek Connie
Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA.
J Pharmacol Exp Ther. 2004 Jul;310(1):407-16. doi: 10.1124/jpet.103.064907. Epub 2004 Mar 15.
A-317491 is a potent and selective antagonist of P2X3 and P2X(2/3) receptors. In the present studies, the ability of [3H]A-317491 to label recombinant human P2X(2/3) and P2X(3) receptors was characterized. Using membranes prepared from 1321N1 cells expressing P2X(2/3) receptors, [3H]A-317491 specifically labeled high-affinity (Kd = 0.9 nM) recognition sites. High-affinity [3H]A-317491 binding was not detected in membrane preparations from native 1321N1 cells or cells expressing homomeric P2X1, P2X2, or P2X3 receptors. Specific [3H]A-317491 P2X3 receptors could only be reliably detected following treatment of intact P2X3 receptor-expressing cells with apyrase (1 U/ml) both before and during membrane preparation. Under these conditions, [3H]A-317491 also labeled high-affinity (Kd = 9 nM) binding sites. Lower affinity binding components (Kd values of 87-790 nM) were detected in both assays using higher ligand concentrations that likely represent nonfunctional recognition sites. [3H]A-317491 binding to both P2X(2/3) and P2X3 receptors was reversible, and ligand kinetic studies provided similar estimates of the high-affinity binding constants. Potent P2X3 receptor agonists 2-methylthio-ATP, 2,3-O-(4-benzoylbenzoyl)-ATP, and alpha,beta-methylene adenosine triphosphate also potently inhibited specific [3H]A-317491 binding to both P2X(2/3) and P2X3 receptors. The pharmacological profile for P2X receptor antagonists to inhibit [3H]A-317491 binding to P2X(2/3) and P2X3 receptors was highly correlated (r = 0.98, P < 0.05), and a similar rank order of potency was observed for blockade of P2X(2/3) receptor-mediated calcium influx. These data demonstrate that [3H]A-317491 is the first useful radioligand for the specific labeling of P2X3-containing channels.
A - 317491是一种强效且具有选择性的P2X3和P2X(2/3)受体拮抗剂。在本研究中,对[3H]A - 317491标记重组人P2X(2/3)和P2X(3)受体的能力进行了表征。使用从表达P2X(2/3)受体的1321N1细胞制备的膜,[3H]A - 317491特异性标记高亲和力(Kd = 0.9 nM)识别位点。在天然1321N1细胞或表达同聚体P2X1、P2X2或P2X3受体的细胞制备的膜中未检测到高亲和力的[3H]A - 317491结合。只有在膜制备之前和过程中用腺苷双磷酸酶(1 U/ml)处理完整的表达P2X3受体的细胞后,才能可靠地检测到特异性的[3H]A - 317491与P2X3受体的结合。在这些条件下,[3H]A - 317491也标记了高亲和力(Kd = 9 nM)结合位点。在两种测定中,使用较高的配体浓度检测到较低亲和力的结合成分(Kd值为87 - 790 nM),这些可能代表无功能的识别位点。[3H]A - 317491与P2X(2/3)和P2X3受体的结合是可逆的,配体动力学研究提供了相似的高亲和力结合常数估计值。强效的P2X3受体激动剂2 - 甲硫基 - ATP、2,3 - O - (4 - 苯甲酰苯甲酰基) - ATP和α,β - 亚甲基三磷酸腺苷也能有效抑制特异性的[3H]A - 317491与P2X(2/3)和P2X3受体的结合。P2X受体拮抗剂抑制[3H]A - 317491与P2X(2/3)和P2X3受体结合的药理学特征高度相关(r = 0.98,P < 0.05),并且在阻断P2X(2/3)受体介导的钙内流方面观察到了相似的效价顺序。这些数据表明,[3H]A - 317491是第一个用于特异性标记含P2X3通道的有用放射性配体。